Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the testing
of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as …

We are witnessing several revolutionary technological advances in cancer. These
innovations have not only contributed to a growing understanding of the tumor and its …

Loss of the von Hippel–Lindau (VHL) tumor suppressor is a hallmark feature of renal clear
cell carcinoma. VHL inactivation results in the constitutive activation of the hypoxia-inducible …

The success of precision oncology—which aims to match the right therapies to the right
patients based on molecular status—is predicated on a robust pipeline of molecular targets …

CDK4/6 inhibitors are remarkable anti-cancer drugs that can arrest tumor cells in G1 and
induce their senescence while causing only relatively mild toxicities in healthy tissues. How …

Abstract TANK binding kinase 1 (TBK1) is an important kinase involved in the innate
immune response. Here we discover that TBK1 is hyperactivated by von Hippel-Lindau …

Inactivation of the VHL tumor suppressor gene is the signature initiating event in clear cell
renal cell carcinoma (ccRCC), which is the most common form of kidney cancer. The VHL …

The treatment of advanced and metastatic kidney cancer has entered a golden era with the
addition of more therapeutic options, improved survival and new targeted therapies …

Renal cancer is a highlyheterogeneous malignancy characterized by rising global incidence
and mortalityrates. The complex interplay and dysregulation of multiple signaling pathways …